Association between serum 25-hydroxyvitamin D and prostate-specific antigen: a retrospective study in men without prostate pathology.

25-hydroxyvitamin D prostate cancer prostate-specific antigen vitamin D

Journal

Advances in laboratory medicine
ISSN: 2628-491X
Titre abrégé: Adv Lab Med
Pays: Germany
ID NLM: 9918284273306676

Informations de publication

Date de publication:
Dec 2023
Historique:
received: 11 08 2023
accepted: 01 10 2023
medline: 18 12 2023
pubmed: 18 12 2023
entrez: 18 12 2023
Statut: epublish

Résumé

Recently, vitamin D status has been associated with prostate cancer risk. However, some studies argue that there is no association of vitamin D with prostate cancer risk and serum prostate-specific antigen (PSA) concentrations. No clear conclusions can be drawn from the studies found in the literature. Our aim was to assess the relationship between PSA and 25-hydroxyvitamin D [25(OH)D]. We selected 415 individuals without prostate pathologies and subgroups were generated according to age and 25(OH)D. Statistical analyses were performed using Shapiro-Wilk test, Student's t and ANOVA tests, and Pearson's correlation. Besides, the minimum sample size needed to obtain statistically significant results between groups according to 25(OH)D concentration was calculated and a Student's t-test for paired samples was performed to study individuals with two PSA measurements over time, where 25(OH)D concentration increased or decreased more than 25 %. We observed a slight correlation between age and PSA concentration (r=0.379, p<0.001). However, we found no significant differences when we compared PSA concentrations between groups according to 25(OH)D concentrations (p=0.891): 1.25 ± 1.32 μg/L (group with 25(OH)D<50 nmol/L) and 1.17 ± 0.90 (group with 25(OH)D≥50 nmol/L). Pearson's correlation coefficient was close to 0. The minimum samples size to obtain statistically significant results was 815,346 men, and we observed no differences in PSA concentrations in individuals with two measurements. Our findings show no association in men without prostate pathologies, based on 25(OH)D levels.

Identifiants

pubmed: 38106489
doi: 10.1515/almed-2023-0104
pii: almed-2023-0104
pmc: PMC10724855
doi:

Types de publication

Journal Article

Langues

eng

Pagination

408-412

Informations de copyright

© 2023 the author(s), published by De Gruyter, Berlin/Boston.

Déclaration de conflit d'intérêts

Competing interests: The authors state no conflict of interest.

Auteurs

Javier Laguna (J)

Department of Biochemistry and Molecular Genetics, CDB, Hospital Clínic of Barcelona, Barcelona, Spain.

Robin Wijngaard (R)

Department of Biochemistry and Molecular Genetics, CDB, Hospital Clínic of Barcelona, Barcelona, Spain.

Susana Hidalgo (S)

Department of Biochemistry and Molecular Genetics, CDB, Hospital Clínic of Barcelona, Barcelona, Spain.

Cristina González-Escribano (C)

CORE Laboratory, CDB, Hospital Clínic of Barcelona, Barcelona, Spain.

Victoria Ortiz (V)

CORE Laboratory, CDB, Hospital Clínic of Barcelona, Barcelona, Spain.

José Luis Bedini (JL)

Department of Biochemistry and Molecular Genetics, CDB, Hospital Clínic of Barcelona, Barcelona, Spain.
CORE Laboratory, CDB, Hospital Clínic of Barcelona, Barcelona, Spain.

Xavier Filella (X)

Department of Biochemistry and Molecular Genetics, CDB, Hospital Clínic of Barcelona, Barcelona, Spain.

Classifications MeSH